Taysha Gene Therapies Stock Surges 49% On FDA Therapy Designation For Rett Syndrome Treatment

(RTTNews) - Taysha Gene Therapies, Inc. (TSHA) soared 49.32 percent to $4.75 on Thursday, up $1.57, after announcing that the U.S. FDA granted Breakthrough Therapy designation to TSHA-102, its AAV9 gene therapy candidate for Rett syndrome. The stock opened at $4.04 and traded between $3.98 and $4.89, compared with a previous close of $3.18 on the Nasdaq. Trading volume surged to 101.23 million shares, far above the average of 3.39 million. Taysha now trades at the top of its 52-week range of $1.05 to $4.89.

The company also finalized alignment with the FDA on the pivotal REVEAL trial protocol and statistical analysis plan, paving the way for a future Biologics License Application submission.